AA
ADMA icon

AlphaCentric Advisors’s ADMA Biologics ADMA Stock Holding History

AlphaCentric Advisors’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$84.9K Buy
10,143
+106
+1% +$966 0.07% 243
2026
Q1 		$90.4K Sell
10,037
-8,745
-47% -$138K 0.09% 221
2025
Q4 		$343K Buy
+18,782
New +$317K 0.34% 94

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

AlphaCentric Advisors's ADMA Position: Q2 2026 in Review

AlphaCentric Advisors increased its ADMA Biologics (ADMA) stake by 1.1% in Q2 2026, buying an estimated $966 and bringing the position to 10,143 shares worth $84.9K. The position accounts for 0.07% of the portfolio, ranked #243.

AlphaCentric Advisors first reported a position in ADMA in Q4 2025 and has held it in 3 quarters since. The position peaked at $343K in Q4 2025. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • AlphaCentric Advisors held 10,143 shares of ADMA Biologics worth $84.9K as of Q2 2026.
  • AlphaCentric Advisors bought 106 ADMA Biologics shares in Q2 2026, an estimated $966.
  • ADMA Biologics made up 0.07% of AlphaCentric Advisors's portfolio in Q2 2026, its #243 holding.
  • AlphaCentric Advisors first reported a position in ADMA Biologics in Q4 2025 and has held it in 3 quarters since.
  • AlphaCentric Advisors's ADMA Biologics position peaked at $343K in Q4 2025.
  • 323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on AlphaCentric Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.